BioRock Ventures Name

PTM Therapeutics is a biotechnology company based in the San Francisco Bay Area that focuses on creating and developing innovative therapies for chronic diseases and cancer. The company specializes in post-translational modification technology, which allows for the identification of disease-specific targets on therapeutic antibodies. This technology distinguishes healthy cells from diseased ones, addressing various biological dysfunctions. By enabling pharmaceutical developers to discover new therapeutic targets, PTM Therapeutics aims to advance the development of effective treatments for challenging medical conditions.

Veana Therapeutics, Inc. is a biotechnology company based in Portland, Oregon, focused on developing innovative immunotherapeutic products for cancer treatment. Founded in 2012, the company specializes in α-TEA-based cancer immunotherapy technologies, which integrate bioavailable anti-cancer agents designed to selectively kill tumor cells while simultaneously stimulating the immune system. This dual action aims to enhance the immunological response in cancer patients, ultimately improving their quality of life during and after treatment. Veana Therapeutics is committed to advancing safe and effective therapeutic options to combat various forms of cancer.

Octagon Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative antibiotic medicines for life-threatening autoimmune diseases such as Pemphigus Vulgaris, Systemic Lupus, and Multiple Sclerosis. Established in 2016, the company aims to address multi-drug resistant infections and has demonstrated effectiveness against critical pathogens identified by the World Health Organization. Octagon specializes in creating targeted immunomodulator therapies designed to reset immune homeostasis in patients suffering from chronic autoimmune and inflammatory conditions. By subtly altering the metabolic processes in immune cells during disease, Octagon's medicines aim to selectively target dysregulated immune cells, thus allowing patients to potentially avoid chronic immunosuppression. The company is housed in the Pagliuca Life Lab, adjacent to Harvard University, which facilitates the rapid development of its critical therapies with minimal overhead. With a management team of skilled scientists, clinicians, and entrepreneurs, Octagon Therapeutics is committed to leveraging extensive research experience in drug development to advance its therapeutic innovations.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists aimed at enhancing innate immunity for cancer immunotherapy. Its TLR7 agonists are designed to stimulate the immune system by producing cytokines and chemokines that boost cellular responses and activate natural killer cells. This approach is intended to complement existing cancer treatments, such as checkpoint inhibitors, improving overall response rates and treatment durability. Primmune Therapeutics' innovative therapies target both acute and chronic viral infections, as well as metastatic diseases, while also promoting B-cell proliferation and activation.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists aimed at enhancing innate immunity for cancer immunotherapy. Its TLR7 agonists are designed to stimulate the immune system by producing cytokines and chemokines that boost cellular responses and activate natural killer cells. This approach is intended to complement existing cancer treatments, such as checkpoint inhibitors, improving overall response rates and treatment durability. Primmune Therapeutics' innovative therapies target both acute and chronic viral infections, as well as metastatic diseases, while also promoting B-cell proliferation and activation.

Seal Rock Therapeutics specializes in the development of small-molecule inhibitors targeting ASK1 (Apoptosis signal-regulating kinase 1), a protein involved in apoptosis, inflammation, and fibrosis. The company primarily focuses on hepatic indications, particularly non-alcoholic steatohepatitis (NASH), a liver condition associated with inflammation and damage due to fatty liver disease. By addressing this significant unmet medical need, Seal Rock aims to provide effective treatment options for NASH and other inflammatory and fibrotic conditions. The potential applications of their ASK1 inhibitors extend beyond hepatic diseases to include cardiac, immunological, and neurodegenerative disorders.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.